Scancell
FY22 results highlight clinical and corporate progressScancell
Optimum partner secured for first antibody dealScancell
First Moditope oncology vaccine enters the clinicScancell
A fresh impetus in delivering immune-oncology vaccinesScancell
CTA approval confirms H221 COVIDITY Phase I startScancell
COVIDITY programme to start Phase I in H221Scancell
H121 results highlight shift to delivery and executionScancell
Redmile funding releases the brakesScancell
Redmile endorses technologies with a further £30mScancell
UKRI awards funding for COVID-19 trial